Global Resipiratory Drugs Market 2016-2020

Global Resipiratory Drugs Market 2016-2020

  • May 2016 •
  • 120 pages •
  • Report ID: 3829258 •
  • Format: PDF
About Respiratory Ailments

Asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and IPF are some of the major respiratory diseases. Among these, asthma and COPD are the most prevalent worldwide. Environmental pollution, changing lifestyles, and hereditary factors are some of the common causes of respiratory diseases. Intranasal corticosteroids, antihistamines, immunosuppressants, bronchodilators, and leukotriene antagonists are the respiratory medicines that are commonly used for the treatment of mild-to-moderate respiratory diseases. However, the choice of drug depends on the type and severity of the disease.

Technavio’s analysts forecast the global respiratory drugs market to grow at a CAGR of 6.48% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global respiratory drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription and over-the-counter (OTC) drugs used to treat respiratory diseases.


The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Respiratory Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- AstraZeneca
- Boehringer Ingelheim
- F.Hoffman La-Roche
- GlaxoSmithKline
- Merck
- Novartis


Other prominent vendors
- Abbott
- Actavis
- Afferent Pharmaceuticals
- Alere
- Almirall
- Amgen
- AptarGroup
- Astellas
- Aurobindo
- Axis Shield
- Baxter
- Bayer
- Biogen
- Biotest
- Bristol-Myers Squibb
- Chiesi Farmaceutici
- Cipla
- Cytos
- Dainippon Sumitomo
- Dr. Reddy's Laboratories
- FibroGen
- Gilead Sciences
- Glenmark
- GNI Group Ltd
- Horizon Pharma
- ImmuneWorks
- MediciNova
- MedImmune
- Mylan
- Ono Pharmaceutical
- Orchid Chemicals and Pharmaceuticals
- Perrigo
- Pfizer
- Promedior
- Prometheus
- ProMetic Life Sciences
- Ranbaxy
- Rottapharm Madaus
- Sanofi
- Shionogi
- Siemens Healthcare Diagnostics
- Skyepharma
- Sosei
Sunovion
- Takeda Pharmaceutical
- Teva
- Theravance
- United Therapeutics
- Vectura
- Vertex
- Zai Lab

Market driver
- Rise in prevalence of respiratory diseases
- For a full, detailed list, view our report

Market challenge
- Unknown etiology of asthma and idiopathic pulmonary fibrosis
- For a full, detailed list, view our report

Market trend
- Use of biologics
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.